WTA
CRL icon

Washington Trust Advisors’s Charles River Laboratories CRL Stock Holding History

Washington Trust Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247 Buy
+1
New +$178 ﹤0.01% 720
2024
Q4 		– Sell
-40
Closed -$7.88K – 655
2024
Q3 		$7.88K Hold
40
– – ﹤0.01% 516
2024
Q2 		$8.26K Sell
40
-29
-42% -$6.57K ﹤0.01% 490
2024
Q1 		$18.7K Hold
69
– – ﹤0.01% 406
2023
Q4 		$16.3K Buy
69
+1
+1% +$197 ﹤0.01% 416
2023
Q3 		$13.3K Hold
68
– – ﹤0.01% 427
2023
Q2 		$14.3K Sell
68
-25
-27% -$4.97K ﹤0.01% 415
2023
Q1 		$18.8K Sell
93
-37
-28% -$8.38K ﹤0.01% 426
2022
Q4 		$28.3K Sell
130
-211
-62% -$46.1K ﹤0.01% 374
2022
Q3 		$67K Sell
341
-82
-19% -$17.7K 0.01% 341
2022
Q2 		$91K Buy
423
+26
+7% +$6.35K 0.01% 310
2022
Q1 		$113K Buy
397
+15
+4% +$4.63K 0.01% 314
2021
Q4 		$144K Buy
+382
New +$148K 0.01% 305

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Washington Trust Advisors's CRL Position: Q2 2026 in Review

Washington Trust Advisors opened a new position in Charles River Laboratories (CRL) in Q2 2026: 1 share worth $247. The stake represents ﹤0.01% of the portfolio and ranks #720 among its holdings. This is a return to the name: Washington Trust Advisors previously reported a position in CRL as recently as Q3 2024.

Washington Trust Advisors first reported a position in CRL in Q4 2021 and has held it in 13 quarters since. The position peaked at $144K in Q4 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Washington Trust Advisors held 1 share of Charles River Laboratories worth $247 as of Q2 2026.
  • Charles River Laboratories was a new Washington Trust Advisors position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #720 holding.
  • Washington Trust Advisors first reported a position in Charles River Laboratories in Q4 2021 and has held it in 13 quarters since.
  • Washington Trust Advisors's Charles River Laboratories position peaked at $144K in Q4 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.